FRYE_HALLORAN SYMPOSIUM IN NEURO-ONCOLOGY by HC120720131716

VIEWS: 9 PAGES: 2

									                 CAROLYN FRYE-HALLORAN SYMPOSIUM
                 CAROLYN FRYE-HALLORAN SYMPOSIUM
                        ON NEURO-ONCOLOGY
                         ON NEURO-ONCOLOGY
                 Massachusetts Generall Hospiitall,, Boston,, MA
                 Massachusetts Genera Hosp ta Boston MA
                       PRIIMARY CNS LYMPHOMA:: FROM BENCH TO BEDSIIDE
                       PR MARY CNS LYMPHOMA FROM BENCH TO BEDS DE
                        R
                                         SEPTEMBER 9--10,, 2004
                                         SEPTEMBER 9 10 2004
                                        PRELIIMIINARY PROGRAM
                                        PREL M NARY PROGRAM

                                            SEPTEMBER 9,, 2004
                                            SEPTEMBER 9 2004
                                              EPTEMBER
                        THE ETHER DOME,, 4TTH FLOOR BULFIINCH BUIILDIING,, MGH
                        THE ETHER DOME 4 H FLOOR BULFINCH BUILDING MGH
                         H E T H E R D O ME  TH
                                                LOOR ULF NCH U LD NG


COMBINED GRAND ROUNDS

8:30 a.m.     Lisa DeAngelis        High dose chemotherapy with stem cell rescue in PCNSL
9:00 a.m.     Henry Friedman        Chemotherapy of Lymphoma – review and outlook

INTRODUCTION AND WELCOME

10:00 a.m.    Dr. Bruce Chabner, Clinical Director, Massachusetts General Cancer Center



TOPIC: BIOLOGY AND EPIDEMIOLOGY OF BRAIN LYMPHOMA AND PTLD

10:15 a.m.    Michael Green         Post-Transplant lymphoproliferation
10:45 p.m.    Elaine S. Jaffe       Immunopathology of lymphoma
11:15 a.m.    Elliott Kieff         Lymphoma and infection: Manifestations and pathogenesis of EBV
                                    disease
11:45 a.m.    Richard Ambinder      Is EBV targeted vaccination a clue in lymphoma therapy? The
                                    activation of immune response against tumor cells

12:30 – 1:45 p.m. Lunch Break. The Tent in the Bulfinch Quadrangle

TOPIC: MOLECULAR PATHOGENESIS AND ITS IMPLICATIONS FOR DIAGNOSIS AND THERAPY

1:45 p.m.     Margaret A. Shipp     Adhesion receptors and tissue-specific dissemination patterns of
                                    lymphoma. Lessons to be learned from Systemic NHL
2:15 p.m.     Massimo Loda          Technology Transfer to the Nervous System
                                             'Technology transfer to the nervous system
2:45 p.m.     James Rubenstein      The Molecular Signature of Lymphoma Cells
3:15 p.m.     Joachim Baehring      The molecular diagnosis of CNS lymphoma - receptor rearrangement
                                    analysis in CSF, vitreous fluid, and tissue
3:45 p.m.     James Rubenstein      Rituximab - Antibody Therapy for CNS lymphoma

7/20/2012
TOPIC: IMMUNOTHERAPY

4:15 p.m.     Helen E. Heslop         Clinical trials in PTLD and similar diseases
4:45 p.m.     Cliona M. Rooney        Strategies to improve efficacy of tumor-specific CTL

7:00 p.m.     Speakers’ Dinner       Harvard Faculty Club

                                            SEPTEMBER 10,, 2004
                                            SEPTEMBER 10 2004
                                    SHRIINER’’S HOSPIITALS FOR CHIILDREN
                                    SHRINER S HOSPITALS FOR CHILDREN
                                      HR NER S OSP TALS FOR H LDREN
                                  SHRIINERS BURNS HOSPIITAL –BOSTON,, MA
                                  SHRINERS BURNS HOSPITAL –BOSTON MA
                                   HR NERS URNS OSP TAL         OSTON
                                         FIIRST FLOOR AUDIITORIIUM
                                          FIRST FLOOR AUDITORIUM
                                            RST LOOR UD TOR UM

TOPIC: THE ROLE OF GENETIC POLYMORPHISM IN MTX RESISTANCE

8:45 a.m.     Joe Bertino             Determinants of response to folate inhibitors
9:15 a.m.     Cornelia Ulrich         Pharmacogenetics - Polymorphisms related to MTX toxicity
9:45 a.m.     pending                 Pemetrexed (Alimta) in lymphoma therapy-dealing with MTX
                                      resistance

10:30 –11:00 Coffee Break

TITLE: DRUG DELIVERY – CHEMOTHERAPY

11:00 a.m.    Ulrich Herrlinger       The German Chemotherapy Trials
11:30 p.m.    Ed Neuwelt              Therapeutic management of brain tumors—the blood brain barrier
12:00 a.m.    Quentin R. Smith        Enhancing drug delivery to brain and brain tumor – Role of the blood-
                                      brain barrier
12:30 p.m.    Andes Ferreri           Outcome parameters of methotrexate therapy (new aspects of
                                      chemotherapy)



1:00P.M.       SUMMARY STATEMENT AND LUNCH.
              INVESTIGATOR IMPLEMENTATION OF COLLABORATIONS.




7/20/2012

								
To top